Aptus Pharma Approves ₹44.88 Crore Raise For Manufacturing Expansion

The Board approved a proposed ₹44.88 crore preferential issue, subject to shareholder and regulatory approvals, to fund ₹25 crore of capex, ₹10 crore of working capital and ₹9.88 crore for general purposes. Aptus targets in-house manufacturing for approximately 20% of product requirements, alongside Pan-India and international expansion.